Orion

71.00 EUR

+1.57 %

14,386 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

+1.57 %
-0.98 %
-2.14 %
+11.55 %
+22.31 %
+26.22 %
+64.35 %
+96.95 %
+532.24 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
10.02B EUR
Turnover
10.87M EUR
P/E (adj.) (26e)
18.11
EV/EBIT (adj.) (26e)
14.11
P/B (26e)
6.28
EV/S (26e)
4.8
Dividend yield-% (26e)
2.51 %
Coverage
Recommendation
Buy
Target price
80.00 EUR
Updated
23.04.2026
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 24.04.2026

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7
2026

Interim report Q2'26

19.10
2026

Half year dividend

28.10
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Views on Orion’s share price can validly be presented within a fairly wide range. This €60 is fine, Inderes’s (Inden) €80 is fine, and the €100 presented by Erkki Sinkko in the media is also fine. This isn’t a bargain-bin stock, but cash is flowing in massively, all the company’s...
4/24/2026, 6:58 AM
by PörssiPatruuna
19
Orion’s results are out, guidance raised as well: Orion-konsernin osavuosikatsaus tammi–maaliskuu 2026 | Kauppalehti January–March 2026 in brief Net sales were EUR 417.7 million (EUR 354.6 million in 1–3/2025) Operating profit was EUR 114.8 (77.9) million Basic earnings per share...
4/23/2026, 9:12 AM
by NukkeNukuttaja
14
Something for a small group of patients, and another step forward as well: orionpharma.com Orion Pharman ODM-212-molekyyli on saanut FDA:n harvinaislääkestatuksen... ORION OYJ LEHDISTÖTIEDOTE 20.4.2026 KLO 16.00
4/20/2026, 2:10 PM
by PörssiPatruuna
14
Antti has made a new company report on Orion We raise our earnings estimates for Orion based on the outlook for Nubeqa, the company’s key earnings growth driver. Bayer, responsible for the sales and marketing of the best-in-class (AR inhibitor) prostate cancer drug, recently provided...
4/1/2026, 5:08 AM
by Sijoittaja-alokas
13
R&D expenses as a percentage of revenue were 11.6% in Q1’26. In the comparison period, Q1’25, the ratio was… 11.6%.
4/23/2026, 10:59 AM
by Verneri Pulkkinen
12
An article in Kauppalehti suggests that Orion’s stock drop today is due to a sharp increase in research and development expenses. On the contrary, a long-term investor should be pleased with significant R&D boosts, especially in the pharmaceutical industry. Overall, it’s a solid,...
4/23/2026, 9:32 AM
by PörssiPatruuna
10
Here’s a new company report from Siltanen after Q1. Orion’s Q1 was again strong and in line with our expectations. Revenue grew by 18% and operating profit by 47%, supported by Nubeqa’s high-margin growth. Among other business areas, Branded Products developed particularly well with...
4/24/2026, 6:11 AM
by Sijoittaja-alokas
9
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.